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and P2 purinoceptors. The length of the phosphate chain deter-In vivo effects of diadenosine polyphosphates on rat renal
mines the degree of vasoconstriction and the extent to whichmicrocirculation.
the substances exert effects on the P2 purinoceptor subtypes.Background. Diadenosine polyphosphates (APXA) are va-
ILOB and AFF are more potently affected by APXA thansoactive nucleotides that elicit effects via purinoceptors. Recent
EFF. Afferent vasodilation is partially overridden by sustaineddata suggest differential effects of APXA on kidney vasculature.
vasoconstriction.Methods. The in vivo effects of AP3A, AP5A, and adenosine
on renal microvessels and the role of purinoceptors were inves-
tigated by the application of agonists to the hydronephrotic
rat kidney and preincubation with respective antagonists.
Diadenosine polyphosphates (APXA) are vasoactiveResults. The addition of the agonists (1027 mol/L up to 1024
purine nucleotides consisting of two adenosine moleculesmol/L) resulted in a concentration-dependent transient vaso-
constriction [interlobular artery (ILOB): adenosine 30 6 7%, linked by a variable number of phosphate groups. APXAs
N 5 7, AP3A 35 6 10%, N 5 5; AP5A 66 6 19%, N 5 have been shown to be present in different cell types
5; 1025 mol/L each] lasting up to one minute, followed by a and to be released from thrombocytes [1–3], as well as
concentration-dependent vasodilation (ILOB: adenosine 10 6
coreleased with catecholamines and adenosine 59-triphos-3%, N 5 6; AP3A 19 6 4%, N 5 5; AP5A 12 6 5%, N 5 6;
phate (ATP) from bovine adrenal medulla [4, 5]. Candi-1025 mol/L each). In ILOB and in the afferent arteriole (AFF),
the constrictory effects of AP5A were more pronounced than date metabolites of APXA are ATP, adenosine diphos-
those of AP3A and adenosine. In the efferent arteriole (EFF), phate (ADP), 39,59-adenosine monophosphate (AMP),
vascular tone was only slightly affected by all agonists. The and adenosine [6], which has been claimed to be the
dilatory potency was comparable for all agonists in ILOB and
mediator of the tubuloglomerular feedback by con-EFF. No significant vasodilation occurred in AFF. The applica-
stricting the afferent arteriole (AFF) [7, 8].tion of the selective A1 receptor antagonist DPCPX (1025
mol/L) completely abolished the adenosine-induced vasocon- APXA have been demonstrated to differentially affect
striction, whereas the A2 receptor antagonist DMPX and the regional perfusion and to influence cardiac output and
P2 purinoceptor antagonists PPADS and A3P5P (all 1025 blood pressure [9], as well as the reactivity of isolated
mol/L) did not affect adenosine-induced constriction. The
blood vessels and vascular beds [10–12]. Furthermore,AP3A-induced constriction was abolished by DPCPX and was
the vascular effects of APXA seem to vary with thepartially inhibited by PPADS. The constriction induced by
AP5A was less sensitive to DPCPX but more sensitive to number of phosphate groups linking the adenosine mole-
PPADS. In ILOB and EFF, DMPX or A3P5P abolished dila- cules [13]. The influence of APXA on central and periph-
tion after the addition of the agonists. The dilation after AP5A eral hemodynamics is currently discussed. Recent data
was not significantly reduced. In AFF, no significant dilation
suggest differential effects of diadenosine polyphosphateswas observed with these agonists alone, but it was clearly visible
on kidney vasculature [9, 14–16].in the presence of DPCPX or PPADS.
Conclusions. APXA evoke transient constrictions in vessels Renal vascular effects induced by APXA and their
of the hydronephrotic rat kidney, which are mediated by A1 metabolites in several models have been reported to be
mediated by A1 and A2 adenosine receptors as well as
P2 purinoceptors [7, 14–23].Key words: split hydronephrotic kidney model, adenosine receptors,
We studied the effects of different diadenosine poly-purinoceptors, renal microvessels, vasoactive nucleotides, hemody-
namics. phosphates (AP3A and AP5A) and of the reference
substance adenosine on renal microvessels in vivo. TheReceived for publication June 1, 1999
model of the split hydronephrotic kidney used in theand in revised form November 24, 1999
Accepted for publication January 2, 2000 present study allows the examination of the microcircula-
tion in almost all segments of the renal vascular tree inÓ 2000 by the International Society of Nephrology
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Table 1. Purinoceptors and the respective antagonistsvivo [24]. Its validity has been well established by the
results in this model compared with those obtained by Antagonist DPCPX DMPX PPADS A3P5P
other approaches for a variety of vasoactive agents [25]. Receptor A1 A2 P2
P2X P2YThe natural tone of the vessels provides an opportunity
Reference [28] [29, 30] [31] [32, 33]to study vasodilation without having to exogenously in-
duce preconstriction in this in vivo approach. The possi-
bility of topical application of drugs prevents systemic
effects of the compounds under investigation. The roles
surements of blood pressure, heart rate, and diametersof A1 and A2 adenosine receptors as well as P2 purinocep-
of the renal vessels at 15 minute intervals. The stability oftors in APXA-induced changes were investigated by
the preparations has been demonstrated for a durationcomparing the effects of these substances on renal micro-
of three hours [27].circulation before and after the addition of their respec-
tive receptor antagonists.
Renal vascular segments and vessel
diameter assessment
METHODS Vessels were identified according to their branching
pattern from a selected glomerulus. Lumen diameters ofPreparation of the hydronephrotic kidney
the following segments were measured: (1) interlobularThe experiments were performed on 43 female Wistar
artery (ILOB), (2) afferent arteriole (AFF), and (3) ef-rats weighing 250 to 270 g and were in accordance with
ferent arteriole (EFF; within 50 mm from the glomeru-the national animal protection guidelines. The technique
lus). Two different kinds of description of the data wereand experimental procedures have been described be-
used. The means of diameters measured at the respectivefore in detail [24, 26]. Unilateral surgical hydronephrosis
time in five up to eight animals form the time-diameterwas induced by permanently ligating the left ureter during
curves. For comparison of the three agonists withoutketamine (Ketaminet, 10% 100 mg/kg body wt intraperi-
admixture or in presence of the antagonists, the respec-toneally; cp-pharma, Burgdorf, Germany) and xylazine
tive maximal values for constriction and dilation of theanesthesia (Rompunt, 10 mg/kg body wt intraperitone-
individual time-diameter curves in each experiment wereally; Bayer, Leverkusen, Germany). Two to three months
used.later, the experiments were conducted under thiobarbital
anesthesia (Inactint, 100 mg/kg intraperitoneally; Byk
Experimental protocolsGulden, Konstanz, Germany). The rats were placed on
Each protocol consisted of 12 periods of five minutesa heated operating table to maintain rectal temperature
each. The diameter of the vessel in focus was measuredat 378C. The trachea was intubated, and the left jugular
each 4 seconds in the first minute, every 10 seconds invein was cannulated for the continuous infusion of saline
the second minute, and at 4 and 5 minutes. To ascertain(50 mL/min), as well as for the infusion of drugs. A
a stable baseline and to assess eventual changes of thepolyethylene catheter was inserted into the left femoral
vessel diameter over the time even without the additionartery for continuous measurement of systemic blood
of exogenous substances, the first five-minute periodpressure. The left hydronephrotic kidney was exposed
served as the control. Visualizing the interlobular artery,by a flank incision and split along the great curvature
a cumulative concentration-response curve for adeno-using a thermal cautery. The dorsal half of the split
sine, AP3A, or AP5A (1026, 1025, 1024 mol/L; Sigma,kidney was sutured to a semicircular-shaped wire frame
Deisenhofen, Germany) was obtained (periods 2 throughand fixed to the bottom of a Plexiglas chamber for intra-
4). After assessing each concentration-response curve,vital transillumination microscopy. The entry of the renal
the bathing medium was exchanged for control medium,hilus into the chamber was sealed with silicon grease,
and after an equilibration time of 10 minutes, the vesseland the chamber was filled with 50 mL of an isotonic,
diameter was measured three times. From these values,isocolloidal solution (Haemaccelt; Behringwerke, Mar-
the mean was determined, which served as a new baselineburg/Lahn, Germany) maintained at 378C with a feed-
for the following concentration-response curve. In pe-back-controlled heating system. The table was then
riod 5, the focus was set on the AFF, and the agonistmounted on the microscope stage; images of microves-
was added at 1025 mol/L. Adding the agonist at 1025sels obtained through a water-immersion objective (Leitz
mol/L in period 6, the EFF was examined. In period 7,Ultropack, UO-55; Leitz, Wetzlar, Germany) were dis-
the effects of receptor antagonists were tested (DPCPX,played on a calibrated monitor by a closed-circuit televi-
DMPX, PPADS, A3P5P; Sigma) the targets of whichsion system and were recorded on videotape. The kidney
are summarized schematically in Table 1. Observing thepreparation was allowed to equilibrate in the tissue bath
interlobular artery, in presence of the antagonist, an-for one hour before starting the experiments, and the
stability of the preparation was tested by repeating mea- other cumulative concentration-response curve with an
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Table 2. Interlobular artery constrictions in percent of the first vasoconstriction evoked by the same concentration of AP5A
Period
AP5A
concentration 2 3 4 W 5 W 6 W 8 9 10 W 11 W 12
1026 mol/L 100 9664
1025 mol/L 100 9861 8969 9363 9564 96 66
1024 mol/L 100 104616
Periods 2 to 12 were 5 minutes each. Abbreviation is: W, washout (10 min each). Data are mean values 6 SEM, N 5 3 animals.
agonist was recorded (periods 8 through 10). Finally, the
effects of this agonist at the concentration of 1025 mol/L
in presence of the antagonist was detected in the AFF
(period 11) and EFF (period 12), respectively.
To preclude that in this in vivo model desensitization
of purinoceptors occurs, we additionally performed three
control experiments in three animals. For these experi-
ments, the same protocol was used as before, except that
the effect of the repetitive addition of the diadenosine
polyphosphate was viewed in the interlobular artery only
and that period 7, the testing of a receptor antagonist,
was skipped. The results are summarized in Table 2,
which provides the effects of AP5A on vessel diameter
as a percentage of the change after the first addition of
the substance in the respective concentration. The data
show that with repeated addition, the agonists evoke
the same effects. Furthermore, there were no significant
differences in the duration of the interval before vasodi-
lation started nor in the degree of the vasodilation found
in the five-minute periods examined in these experi-
ments.
Data analysis including statistical analysis
The data are presented as means 6 SEM. Changes in
vascular diameters are presented as a percentage of the
preceding control value. The time course of mean
changes in vessel diameter was processed from mean
intrarenal vessel diameters 6 SEM at the respective
times of measurement (Fig. 1). Since peak changes in
vessel diameter occurred at variable time points, all fur-
ther data are derived from minimal vessel diameters
during the early phase and maximal late phase diameters
of the renal microvessels (Figs. 2–5). The statistical sig-
nificance was determined by analysis of variance for mul-
tiple comparisons, Student-Newman-Keuls test, and
paired and unpaired t-tests as appropriate. The overall
significance level was set to P , 0.05.
Fig. 1. Time course of mean changes in intrarenal vessel diameter after
the application of AP5A. The curves show the mean intrarenal vessel
RESULTS diameters 6 SEM at the respective times of measurement. (A) Effect
of AP5A [1026 mol/L (r) up to 1024 mol/L] on interlobular arteryTopical application of adenosine, AP3A, and AP5A diameter. Only AP5A 1025 mol/L (.) and 1024 mol/L (r) showed
to the hydronephrotic rat kidney evoked a transient con- significant constrictions in this segment. Symbol (n) is control. (B)
Effect of AP5A (1025 mol/L) on the diameters of afferent (h; AFF)striction, which was followed by a discrete vasodilation.
and efferent (s; EFF) arterioles. AFFs were constricted significantly,The peak constrictory effect developed in 10 to 20 sec- while the mean EFF diameters did not change significantly. The number
of animals was five to eight. *P , 0.05 vs. baseline.onds (early phase), and the vessel diameter returned to
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Fig. 2. Comparison of maximal constrictory
responses of adenosine AP3A or AP5A on
interlobular artery, afferent, and efferent arte-
riole diameters. (A) Concentration-response
curves of the maximal constrictions elicited by
adenosine (d), AP3A (.), and AP5A (h) on
the interlobular artery. The curve for AP5A
significantly differs from those of adenosine
and AP3A. (B) Comparison of early-phase
maximal constrictions of interlobular artery,
AFF, and EFF after application of adenosine
(j), AP3A ( ) and AP5A (h) at a concentra-
tion of 1025 mol/L each. All agonists signifi-
cantly constricted every segment examined
compared with baseline. The effects of AP3A
and AP5A were significantly more pro-
nounced in interlobular artery and AFF than
in EFF. In both preglomerular segments,
AP5A was more effective than AP3A and
adenosine (N 5 5 to 8). *Statistical signifi-
cance of the difference (P , 0.05).
baseline levels within 1 to 2 minutes. After three minutes AP3A, which was slightly more effective in doing so than
adenosine.(late phase), vessel diameters stabilized above baseline
As can be deduced from Figure 3A, in the late phase,levels. As an example of the three agonists used, Figure 1
the three agonists dilated the ILOB concentration de-depicts the time course surveyed after local application of
pendently. The curves do not differ significantly, indicat-AP5A (1026 mol/L up to 1024 mol/L) in the ILOB (Fig. 1A)
ing a similar potency of the three agonists in dilatingand the effects of AP5A (1025 mol/L) monitored in AFF
the ILOB. While application of adenosine and AP3Aand EFFs (Fig. 1B). In Figure 1, the first kind of descrip-
induced vasodilation in the interlobular artery (Fig. 3B),tion of the data is used. In contrast to all other graphs,
the addition of adenosine and AP3A failed to induce athe time diameter curves of Figure 1 are formed by the
significant dilation in the AFF in the five minute periodmeans of the change of vessel diameters measured at the
examined in this study. In this interval, the AFF re-respective time. While AP5A at the concentration of
mained vasoconstricted after the application of AP3A.1026 mol/L did not significantly reduce the mean diame-
Also, in this observation period AP5A neither signifi-ter of the ILOB at the respective time, nor did it so at 1025
cantly dilated the ILOB nor AFF as a consequence ofmol/L in the EFF, AP5A clearly induced constrictions at
ongoing vasoconstriction. The EFF showed a slight dila-1025 and 1024 mol/L in the ILOB and in the AFF.
tion after the addition of all three agonists. Thus, inas-
To compare the three agonists without admixture or in
much the AFF shows a long-lasting constriction after
presence of the antagonists, the means of the respective application of the agonists, the diameter changes of this
maximal changes (constriction or dilation, respectively) last preglomerular segment differ from those patterns of
during the early or the late phase of the individual time- interlobular artery and EFF.
diameter curve in each experiment were used (Fig. 2–5). To test the role of adenosine receptors and P2 purino-
Adenosine, AP3A, and AP5A constricted renal micro- ceptors in mediating the effects of diadenosine polyphos-
vessels concentration dependently (Fig. 2). In the ILOB, phates on renal microvasculature, we examined the effect
AP5A was more potent in doing so than AP3A and of adenosine and AP3A as well as AP5A in the presence
adenosine (Fig. 2A). Figure 2B compares the early phase of respective receptor antagonists. Topical application of
minimal diameters of the ILOB of AFF and EFF after the antagonists themselves did not exert significant ef-
application of adenosine, AP3A, and AP5A at the con- fects on intrarenal vessel dimensions (data not shown).
centration of 1025 mol/L. The three agonists constricted Figure 4 summarizes the maximal constrictory effects of
all vessels significantly in comparison to baseline values. adenosine (Fig. 4A), AP3A (Fig. 4B), and AP5A (Fig. 4C)
The effects were significantly more pronounced in the on interlobular artery without an admixture and in the
ILOB and the AFF than in the EFF. AP5A more po- presence of the A1-antagonist DPCPX, the A2-antagonist
DMPX, or the P2-antagonists PPADS or A3P5P (1025tently constricted both preglomerular segments than
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Fig. 3. Maximal dilatory effects of adenosine,
AP3A and AP5A. (A) Concentration-response
curves of the maximal dilations induced by
adenosine (d), AP3A (.) or AP5A (h) on
interlobular artery (ILOB). All three agonists
similarly increased the vessel diameters. (B)
Comparison of late-phase maximal diameter
changes of ILOB, AFF, and EFF after applica-
tion of adenosine (j), AP3A ( ), and AP5A
(h), 1025 mol/L, each. In the ILOB, adenosine
and AP3A and in the EFF, all antagonists
increased the vessel diameters. In the AFF,
no significant dilation could be observed. The
number of animals was 5 to 8. *Significant
difference vs. baseline (P , 0.05).
Fig. 4. Effects of DPCPX, DMPX, PPADS, and A3P5P on maximal constrictions elicited by adenosine, AP3A, or AP5A in the interlobular
artery. (A) The effect of adenosine was significantly inhibited by DPCPX only. (B) The effect of AP3A was completely inhibited by DPCPX and
was partially reduced by 1025 mol/L DMPX, PPADS, or A3P5P. (C) The effect of AP5A was partially reduced by DPCPX, PPADS, or A3P5P.
The number of animals was five to eight. Symbols are: (j) agonists; (r) DPCPX; (m) DMPX; (s) PPADS; (n) A3P5P.
mol/L, each). The concentration-dependent constriction tor agonism with adenosine to a more pronounced P2-
purinoceptor agonism with AP5A, while the profile ofinduced by adenosine was abolished by the A1-adenosine
receptor antagonist DPCPX, whereas the A2-adenosine AP3A was intermediate.
Figure 5 summarizes the effects of purinoceptor an-receptor antagonist DMPX, as well as the P2-purinocep-
tor antagonists PPADS and A3P5P did not change the tagonists (1025 mol/L) on late-phase vessel diameter of
interlobular artery (Fig. 5A), AFF (Fig. 5B), and EFFeffect of adenosine significantly. DPCPX reduced the
constrictory effect of AP3A as well, while the addition (Fig. 5C) induced by agonists at the concentration of
1025 mol/L. It can be deduced that the impairment ofof AP3A in the presence of DMPX or PPADS was still
followed by a concentration-dependent constriction, interlobular artery vasodilation by the A2-antagonist
DMPX and the P2-antagonist A3P5P was mirrored bywhich was significantly reduced at 1024 mol/L. The effects
of AP5A without admixture differed significantly from the antagonist effects in AFF and EFF. The A1-antago-
nist DPCPX was without any effect in the late phase inthose achieved in presence of DPCPX, PPADS, or
A3P5P. The agonistic profile for the effects of adenosine, the two latter vessels. The P2-antagonist PPADS par-
tially reduced the dilation induced by AP3A and adeno-AP3A, and AP5A shifted from pure A1-adenosine recep-
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Topical application of all agonists and antagonists had
no effect on the heart rate or mean arterial pressure.
DISCUSSION
Renal hemodynamics are affected by diadenosine poly-
phosphates [9, 15, 16]. Our study evaluated their effects
on intrarenal microvasculature by analyzing interlobular
artery as well as afferent and efferent arteriole diameters
after application of AP3A, AP5A, or adenosine (which
was regarded as a reference substance) to the split hydro-
nephrotic rat kidney. As in intact animals, various isolated
vascular beds, and arteries of several species [3, 9, 12, 34],
topical application of APXA induced constriction in re-
nal microvessels of this model. As in perfused rat mesen-
teric arteries [13] and the isolated perfused rat kidney
[15], the administration of AP5A was followed by a more
intense and longer lasting constriction than admission of
AP3A. In line with the higher affinity of especially AP5A
and AP6A for P2X purinoceptors in ligand binding stud-
ies [35], AP5A was the more potent contractile agonist.
The fact that AP5A caused a more intense vasocon-
striction than AP3A and adenosine in the preglomerular
vessels, which had similar effects, contrasts with the find-
ing of equal and less overall pronounced constrictory
potencies for the EFF of the three agonists. This suggests
a more intense involvement of P2 purinoceptor activa-
tion in preglomerular vasoconstriction as compared to
efferent vasoconstriction. This conclusion parallels with
the findings of Inscho, Mitchell, and Navar, who found
that ATP, a P2 agonist, constricts AFF but not EFF,
whereas adenosine constricts both vascular segments
[19]. Of the major segments of the intrarenal microvas-
culature, the AFF is most responsive to ATP [36], which
is in line with our finding that after a transient constric-
tion caused by the addition of the agonist, AFF does not
dilate unless P2X purinoceptors are blocked.
Degradation of the agonists as a cause for the transient
Fig. 5. Comparison of the effects of DPCPX, DMPX, PPADS, or
nature of the vasoconstriction could be excluded, be-A3P5P (1025 mol/L each) on adenosine (j), AP3A ( ), or AP5A
(h)-induced maximal changes in late phase vessel diameter. Effects in cause the same medium that exerted a transient vasocon-
the interlobular artery (A), in the afferent (B), and the efferent arteriole striction was effective in repeatedly inducing comparable
(C) elicited by the agonists alone (1025 mol/L, each) and in presence
constrictions when it was collected from the bath afterof the antagonists (1025 mol/L, respectively). DMPX and A3P5P re-
duced the dilation evoked by all three agonists in the ILOB and the five minutes and added again after exchanging with con-
EFF. PPADS partially reduced the effects of adenosine and AP3A in trol medium. Control experiments that followed the 12-
the ILOB. AFF dilation got visible in presence of DPCPX or PPADS.
period scheme demonstrate that repeated administrationThe number of animals was five to eight. *Significance of the effects
vs. baseline (P , 0.05). of APXA reproducibly constricted renal vessels. Thus,
neither agonist degradation nor receptor desensitization
occurred. This also suggests that desensitization is not
responsible for the transient character of the effects.sine in the interlobular artery. Interestingly, the AFF,
Osswald reported that there was an initial reduction ofwhich remained constricted or at least was not dilated
renal blood flow during continuous infusion of adenosinesignificantly by the agonists, clearly showed vasodilation
into the renal artery, which then returned or rose slightlyafter application of DPCPX and PPADS. Thus, the un-
above preinfusion levels within one to three minutes [7].derlying vasodilation was demasked by the addition of
Holz and Steinhausen found stable adenosine analoguesthe A1-adenosine receptor antagonist and the P2-purino-
ceptor antagonist PPADS. to affect the vessel diameter continuously [37]. Here we
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report transient constrictory effects of adenosine as well vasodilatory response to APXA [10, 42] render it less
likely that the P2-agonists initiate the dilation by a gener-as of APXA. These dual effects of APXA and adenosine
in microvessels of the hydronephrotic rat kidney are in ation of endothelium-dependent vasodilators, although
rat renal purinoceptor-mediated vasodilation has beenline with data showing that APXA evoke a biphasic
blood pressure response to APXA in anesthetized rats shown to be converted to vasoconstriction by nitric oxide
synthase inhibition with an application of the agonist[9]. Interestingly, Inscho states that microvascular re-
sponses to adenosine include vasoconstriction at low from the endothelial side [40, 41] and removal of the
endothelium of intrarenal vessels converted vasodilationdoses and vasodilation at higher concentrations [18]. The
vasoconstriction is elicited in both preglomerular and to constriction [41]. However, Inscho et al concluded
that in superfused, blood-perfused rat juxtamedullarypostglomerular arterioles. Furthermore, Inscho, Ohishi,
and Navar reported arcuate and interlobular arteries to afferent nephrons, partial relaxation of ATP-constricted
interlobular arteries and AFF was not due to endogenousexhibit transient vasoconstrictions with ATP, while in
contrast, it evoked a sustained reduction in the afferent nitric oxide [21].
The effects of purinoceptor antagonists indicated thearteriolar diameter, with the EFF remaining unchanged
[36]. The fact that AP3A and AP5A, in contrast to ATP, role of respective receptors in mediating the effect of
APXA on renal microvasculature. While there are selec-elicit transient effects also in the AFF indicates that
these agonists probably provoke purinoceptor mediated tive antagonists for the adenosine receptor subtypes, the
selectivity of PPADS and A3P5P for the P2-purinocep-vasodilation. This is further supported by the finding that
after inhibition of A1 adenosine or P2X receptors, the tor subtypes is limited (Table 1). As expected, DPCPX,
the A1-receptor antagonist, completely abolished adeno-AFF dilated after an addition of these agonists.
APXA have been observed to induce arterial relax- sine-induced vasoconstriction, whereas the A2-antago-
nist DMPX and the P2-antagonists PPADS and A3P5Pation in several vascular beds [15, 38] and in isolated
agonist-constricted rat mesenteric arteries [13]. It was had no significant effects. In the isolated perfused rat
kidney, the constriction by AP3A was mostly due to A1-excluded that the relaxing responses were mediated by
metabolites generated by asymmetric cleavage of the receptors, that by AP4A to A1- and P2X-receptors, and
the constrictive response to AP5A was due to P2X-puri-APXA [6, 10, 39]. Comparing the constrictory and dila-
tory potencies of adenosine and the APXA, it is evident noceptor activation [15, 16]. Similarly, we found a com-
plete inhibition of AP3A-induced vasoconstriction byfrom the present study that metabolism of APXA to
adenosine does not account for the observed effects. In the A1-antagonist, but only partial effects of the A2- or
P2-antagonists. Instead, the vasoconstriction induced byour system, intrarenal vessel diameters were similarly
augmented by adenosine, AP5A, and AP3A in the late AP5A was antagonized most effectively by the P2-recep-
tor antagonist. Intravenous bolus administration of P2-phase after agonist addition. The interlobular artery and
EFF were dilated to a similar extent, while the AFF receptor subtype agonists increase renal and mesenteric
resistance and arterial pressure in rats [17]. In the presentdiameter was not significantly augmented. The latter
finding may be the consequence of a more intense vaso- study, AP5A, in comparison to adenosine and AP3A,
was less sensitive to the A1-antagonist DPCPX but wasconstriction in this segment.
Intrarenally infused P2Y agonists dilate renal vessels more sensitive to the P2-antagonists PPADS and A3P5P,
indicating that the vasoconstriction is mediated by A1-[40, 41]. It has been reported that by contacting the
smooth muscle from the adventitial side after superfu- receptors and P2-purinoceptors. The lack of efferent
P2X-receptor expression [43] clarifies our finding thatsion, no significant afferent arteriolar vasodilation occurs
[21]. Released from thrombocytes, APXA may gain ac- PPADS does not change the effect of adenosine, AP3A,
or AP5A in this segment.cess to their receptors from the lumen. On the other
hand, endogenous purine nucleotides are released from Comparable to the vasodilation evoked by AP3A in
a raised tone preparation of the isolated perfused ratsympathetic nerve varicosities or in a paracrine fashion
from cells neighboring the renal microvasculature. Nu- kidney, which was blocked by the A2 antagonist DMPX
[15], the vasodilation seen with adenosine, AP3A, andcleotides released from these sources are delivered to
the interstitial fluid where they interact with P2-receptors AP5A in the present study was antagonized by the A2-
antagonist DMPX and by the P2-antagonist A3P5P. Coxon microvascular smooth muscle, mesangial cells, or tu-
bular and glomerular epithelium. In our study, the appli- and Smits reported a decrease in cerebral, coronary, and
mesenteric but no effects on renal vascular resistancecation of the substances to the bath most likely resulted
in abluminal access of the APXA to the receptors activat- after P2Y-receptor activation [17]. As expected, the late-
phase vasodilation evoked by adenosine, AP3A, anding the smooth muscle receptors first, whereas in the
isolated perfused rat kidney, compounds that are admin- AP5A was not altered by the A1 antagonist DPCPX nor
by the P2-antagonist PPADS. While the pattern of late-istered to the luminal side meet the endothelial cells first.
This and the absence of endothelial involvement in the phase responses to the antagonists was similar and clear
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